- Home
- GH vs BIPC Comparison
GH vs BIPC Comparison
Compare GH & BIPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- BIPC
- Stock Information
- Founded
- GH 2011
- BIPC 2019
- Country
- GH United States
- BIPC United States
- Employees
- GH N/A
- BIPC N/A
- Industry
- GH Medical Specialities
- BIPC Marine Transportation
- Sector
- GH Health Care
- BIPC Consumer Discretionary
- Exchange
- GH Nasdaq
- BIPC Nasdaq
- Market Cap
- GH 4.9B
- BIPC 5.4B
- IPO Year
- GH 2018
- BIPC N/A
- Fundamental
- Price
- GH $98.28
- BIPC $45.15
- Analyst Decision
- GH Strong Buy
- BIPC Hold
- Analyst Count
- GH 22
- BIPC 1
- Target Price
- GH $74.32
- BIPC $46.00
- AVG Volume (30 Days)
- GH 3.4M
- BIPC 637.3K
- Earning Date
- GH 10-29-2025
- BIPC 01-01-0001
- Dividend Yield
- GH N/A
- BIPC 3.85%
- EPS Growth
- GH N/A
- BIPC N/A
- EPS
- GH N/A
- BIPC N/A
- Revenue
- GH $902,569,000.00
- BIPC $3,656,000,000.00
- Revenue This Year
- GH $33.95
- BIPC $3.27
- Revenue Next Year
- GH $25.77
- BIPC $5.78
- P/E Ratio
- GH N/A
- BIPC N/A
- Revenue Growth
- GH 30.38
- BIPC 11.38
- 52 Week Low
- GH $28.45
- BIPC $32.08
- 52 Week High
- GH $101.57
- BIPC $47.71
- Technical
- Relative Strength Index (RSI)
- GH 77.88
- BIPC 51.38
- Support Level
- GH $88.88
- BIPC $44.54
- Resistance Level
- GH $97.51
- BIPC $46.88
- Average True Range (ATR)
- GH 4.94
- BIPC 1.29
- MACD
- GH 1.89
- BIPC -0.11
- Stochastic Oscillator
- GH 88.05
- BIPC 46.68
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About BIPC Brookfield Infrastructure Corporation
Brookfield Infrastructure Corp is an indirect subsidiary of the partnership of the diversified infrastructure owner and operators. Its business is comprised of a U.K. regulated distribution operation, a Brazilian regulated natural gas transmission operation and an international intermodal logistics operation. Geographically, the company generates a majority of its revenue from Brazil and rest from United Kingdom and the United States.